Abstract Objective: To assess the epidemiological and clinico-pathological features, surgical and reconstructive techniques, adjuvant treatments and clinical outcome of breast carcinoma in males (BCM) at the Egyptian National Cancer Institute (NCI). Patients and methods: Thirty-two males with breast carcinoma presented to NCI between January 2000 and December 2002. They were evaluated by complete history, physical examination, laboratory and radiological investigations. Results: Median age was 59 years. Left sided and retroareolar breast lumps were the commonest presentations. Grade II tumors positive for hormone receptors were very common. Stage I, II, III and IV disease were encountered in 6.2%, 34.4%, 34.4% and 25.0% of patients, respectively. Curative surgery was done in 22 patients; they received adjuvant hormonal therapy, chemotherapy and radiotherapy in 22, 16 and 10 patients, respectively. Eight metastatic patients were treated with palliative measures. Surgery was done in 25 patients; the most common procedure was modified radical mastectomy (40.6%). Primary closure was feasible in 17 patients (68%), local flaps were * Corresponding author. Address:
Introduction
Breast carcinoma in males (BCM) is relatively a rare disease that accounts for 1% of all breast cancer and less than 1% of all cancers in men [1] [2] [3] [4] . However BCM incidence has increased over the past 25 years [5] [6] [7] .
The natural history and prognostic factors parallel those of breast carcinoma in females (BCF). The differences are older age at presentation, higher rate of estrogen receptor positivity (90% vs. 60%, approximately), different distribution of histological subtypes with more preponderance of the ductal histology in males and higher stage at presentation [5, 8] .
The aim of this retrospective study was to assess the clinicopathological features of BCM at the Egyptian National Cancer Institute (NCI) and to review different surgical treatments and reconstructive techniques, the role of adjuvant treatments, and the clinical outcome.
Patients and methods
From January 2000 to December 2002, 32 male patients with breast carcinoma presented to the NCI, 24 patients of them (75%) had loco-regional disease while 8 patients (25%) presented with metastatic disease. All patients under-went full laboratory investigations, chest radiography, and abdominal ultrasound. Bone scan was done when indicated (large tumors, positive nodes or suspected bone metastases). Pathological diagnosis was obtained by different diagnostic procedures including incisional biopsy in 14 patients (43.8%), true-cut needle biopsy in 8 patients (25.0%), excisional biopsy in 3 patients (9.3%), fine needle aspiration cytology in 2 patients (6.3%) and frozen section in 5 patients (15.6%). The epidemiological factors studied were patients' demographic characteristics, family history, presentation, stage at diagnosis, investigations, details of treatment, pathology including tumor size and grade, nodal status and hormone receptor status. All patients were pathologically staged using the sixth edition of the AJCC Cancer Staging Manual of Breast cancer criteria [9] . Overall survival was calculated from the date of pathological diagnosis to date of death or last follow up. Disease free survival was calculated from date of surgical intervention to date of recurrence or death or last follow up. Patients were followed up to the end of December 2010.
Statistical methods
Data was analyzed using SPSS win statistical package version 15. Quantitative data were presented as median and range. Qualitative data were expressed as frequency and percentage.
Survival analysis was done using Kaplan-Meier method and presented as cumulative survival rates. Comparison between two survival curves was done using Log-rank test. A p-value <0.05 was considered significant.
Results
Thirty-two patients with BCM were studied during the aforementioned time period. They represented only 0.89% of all cases of breast carcinoma who presented to the NCI in the same period. The median age at diagnosis was 59 years, ranging between 31 and 87 years. Those younger than 50 years were 28.1%. Thirteen patients (40.6%) were farmers. The majority of patients were smokers (84.4%). Nineteen patients (59.4%) had history of bilharziasis. Only 3 patients (9.3%) had a positive family history in a 1st degree relative female (Table 1) .
Most patients presented by a breast lump (25 cases, 78.1%) with slight predilection of the lump to the left side (Fig. 1) . The majority of the lumps occupied the retroareolar region (23 cases, 71.9%) ( Table 2 ). The median delay between complaints and clinical presentations was 11 months (range: 2-37 months). Gynecomastia was present only in 2 cases (6.3%). Most patients presented with loco-regional disease and only 8 cases (25.0%) were metastatic at presentation. (Table 3) . Two patients (6.3%) refused surgical treatment and lost to follow-up (Fig. 2) . Out of the 30 patients whose management data was documented, hormonal therapy, chemotherapy and radiotherapy were used in 100%, 73.3%, and 43.3%, respectively. Hormonal therapy (tamoxifen) was used as adjuvant to surgery in 22 cases (73.3%); and as palliative measure in 8 cases (26.7%). Chemotherapy was used as adjuvant to surgery in 16 cases (53.3%) and as a palliative measure in 6 cases (20.0%). Anthracycline-containing chemo-therapies (FAC/ FEC) were the most common (18/22; 81.8%). Radiotherapy was given as adjuvant to surgery in 10 patients (33.3%) and was palliative in 3 patients. The 8 patients (26.7%) with distant metastases were treated by palliative hormonal therapy with or without chemotherapy and radiotherapy (Table 3) .
For the 25 cases where mastectomy was done, primary closure was feasible in 17 cases (68%) (Figs. 3 and 4), local flaps were needed in 4 cases (16%) while pedicled latissimus dorsi myocutaneous flap (MCF) was done in 3 (12%) cases (Fig. 5 ). In only one patient (4%) with T4 lesion resection of part of the chest wall (3 ribs) was needed, where reconstruction was done by bone cement with double prolene mesh covered by pedicled rectus abdominus myocutaneous flap ( Table 3) . The most common complications encountered were the development of seroma (9 cases; 36%), followed by partial edge sloughing in 3 cases (12%) (Fig. 4) , wound infection in 1 patient (4%) and liver failure in 1 patient (4%).
During the course of this study, local recurrence developed in 3 patients (13.6%) of those who underwent curative surgery (22 patients), while distant metastases developed in 7 patients (31.8%). One patient developed both local recurrence and distant metastases. After a median follow up of 58 months (range: 1-132 months), 8 patients (25%) were dead of breast cancer, 16 were living free of disease (50%) and six were living with evidence of disease (19%). Two patients with non-metastatic disease refused surgery and did not show up again. The cumulative overall survival (OS) for the whole group at 3, 5 and 10 years was 77.9%, 65.4% and 57.2%, respectively. The cumulative disease free survival (DFS) for the 22 patients who underwent curative therapy at 3, 5 and 10 years was 70.0% and 53.9% and 53.9%, respectively (Fig. 6) . Age, side, site, stage, lymph node (LN) status and type of surgery were analyzed to identify the significant variables affecting the overall and disease free 5 year survival (Tables 4 and 5 Regarding disease free survival, surgery type ( Fig. 9 ) was the only variable significantly affecting survival (p = 0.002), and stage has a borderline significant effect (p = 0.123). 
Discussion
Breast carcinoma in males (BCM) is relatively a rare disease that accounts for 1% of all breast cancer and less than 1% of all cancers in men [1] [2] [3] [4] . The global distribution of BCM is similar to that of BCF (i.e. BCM is very rare in areas with a low incidence of breast cancer in general), with few exceptions. It was reported in the past that BCM is common in Egypt, an area of relatively low BCF incidence, probably because of high rates of schistosomiasis-related liver diseases [10] . In our study BCM represented only 0.89% of all breast carcinomas presenting to our institute in the same matched period. Figure 6 Postoperative specimen, part of the pectoralis major muscle underneath the tumor was taken as safety margin. 
Epidemiology and management of breast carcinoma in Egyptian males: Experience of a single Cancer Institute
This percentage is much less than 2 earlier studies in Egypt where BCM represented 9.5% and 6.4% of all breast carcinomas [11, 12] . In a combined 3 Egyptian hospital materials including (Kasr El Aini hospital, Cairo, Government hospital, Alexandria and Faculty of Medicine hospital, Alexandria) BCM represented 6.4% in a total of 706 cases of breast carcinoma [12] . The authors in these earlier studies suggested hyperestrogenism of the liver caused by bilharziasis as one possible explanation of the relatively high frequency of BCM in these early reports. Compared to earlier studies, the low frequency of BCM in our study may be attributed to the effective prevention and early treatment of bilharziasis in Egypt.
The median age of BCM at diagnosis is 68 years; however, the disease has been reported in males ranging from 5 to 93 years. The greatest incidence occurs 5-10 years later in males than in females with the vast majority of cases occurring in the fifth and sixth decades [5, 8, 13] . The annual incidence of BCM increases steadily lacking the premenopausal peak seen in females [2] . In our study the median age of BCM was 59 years while the median age of BCF presenting in the same period was 49 years.
Factors associated with the development of BCM include conditions of relative hyperestrogenism [14] , testicular dysfunction due to chromosomal abnormality such as Klinefelter's syndrome [15] or environmental factors such as chronic heat exposure [16] and previous chest wall irradiation especially in childhood malignancies [17] . In our study 19 cases had positive past history of bilharziasis which may be a risk factor attributed to possible associated bilharzial liver fibrosis.
Approximately 30% of BCM have positive family history of BCM or BCF [1] . Breast cancer in a first-degree relative was reported in 14% in one series [18] . Most cases of BCM are sporadic but a familial form exists in which both males and females show an increased risk of developing breast cancer [10] . In men, BRCA-1 does not appear to be associated with a significantly increased risk of breast cancer. However men with BRCA-2 mutations are predisposed to breast cancer [19] . In our study only 3 cases had positive family history of BCF in first degree relatives.
For men, the overall risk of BCM among BRCA-2 mutation carriers is 6%. However in females the implications of discovering a BRCA-2 mutation are much greater because such mutations confer on these persons a 56-87% BCF risk by age 70 [20] . Dı´ez and colleagues [19] insisted that all new cases of BCM should be regarded as being possibly inherited and should be fully investigated especially if potential transmissions of BRCA-2 mutations to female offspring are involved.
Almost 85% of BCM present with a unilateral slightly irregular firm, painless or minimally tender, subareolar mass often eccentric with rare nipple involvement and there is a slight predilection for left breast with a ratio of left to right of 1.07:1 [21, 22] . In the present study, most cases presented with breast lump (78.1%) with a slight predilection to the left side (59.4%). Seventy-two percent of cases were in the retroareolar region. Breast cancer tends to present at later stages in males than in females [5, 6, 13, 23] .
In this study, the mean delay between complaint and presentation was 11.5 months, which resulted in advanced stage at presentation (11 cases with stage III, and 8 cases with stage IV). Great attention and awareness for the males on the prevalence and risk factors for this disease should be taken to achieve early detection of these cases. Also males with breast carcinoma require proper psychological support [6, 15] .
Although open biopsy was considered the gold standard for the evaluation of BCM, nowadays the non-operative evaluation of breast masses in BCM can employ either cytology (FNA) or core biopsy, depending on different institutions experience [24] . In our study, pathological diagnosis by open biopsy was done in 22 cases of which 15 cases were already done outside our institute which is considered a tertiary center in Egypt.
Approximately 90% of all breast tumors in men are invasive carcinomas, the remaining 10% are non-invasive. Eighty percent of all tumors are infiltrating duct carcinoma as normal male breast contains only ductal tissue and does not contain lobules; lobular carcinoma is much less common than in females and represents only 1% of cases. Non-invasive carcinomas in men are low to intermediate grade ductal carcinoma in situ (DCIS) whereas; pure lobular CIS is extremely rare [25, 26] . Histopathological examination of tumors in our study revealed that all cases (100%) were invasive ductal carcinoma, and almost all cases were of intermediate grade (grade II).
Most cases of BCM are ER positive (65-94%) compared to 60% in women therefore, most of patients will be treated with tamoxifen or will respond to hormonal manipulation than with female patients. Similarly, BCM is more commonly PR positive (93%) [27] . The present series confirmed the high prevalence of ER positivity in male breast cancer patients (83.3%).
Surgical excision is the mainstay treatment for BCM. Although radical mastectomy was traditionally the treatment of choice because of the paucity of male breast tissue and the resultant proximity of these lesions to chest wall, surgical therapy has evolved towards more limited procedures. A 30-year review of 170 cases treated at the National Cancer Institute of Italy in Milan noted a trend from RM to MRM and finally total mastectomy TM for (smaller and DCIS lesions) in the later period of study [28] . A similar surgical trend was noted in the United States [18] . In the present study, the majority of cases were treated by MRM (13 cases); RM was done in (9 cases), while simple mastectomy was done in three metastatic patients with marked tumor ulceration and fungation. Most of these cases were closed primarily after mastectomy (17 cases). In 8 cases reconstruction by flaps was needed. Local skin flaps were done in 4 cases while pedicled latissimus dorsi myocutaneous flap was done in 3 cases. Pedicled rectus abdominus myocutaneous flap with bone cement and double prolene mesh was done in only one case with chest wall defect after mastectomy in T4 lesion.
Tamoxifen is accepted as first-line adjuvant therapy for receptor-positive BCM and is often used alone [5, 15, 27, [29] [30] [31] . Because BCM is a rare disease, there are no large randomized trials that support the use of adjuvant chemotherapy or trastuzumab. However, given the confirmed results regarding BCF and the positive experiences in men, both men and women could share the same guidelines for adjuvant treatment. Chemotherapy is proposed in young men with axillary nodal involvement and/or negative hormone receptors [30, 31] . Despite adjuvant radiotherapy (RT) appears to reduce loco-regional recurrences, survival benefit is unknown. Men may have higher risk of internal mammary nodal disease and thus could theoretically benefit from internal mammary radiation [5, 30, 32] . In our study, tamoxifen was given either postoperatively as an adjuvant therapy to all operable cases, or to metastatic cases as a palliative therapy. Chemotherapy was given as adjuvant treatment in 16 patients and as palliative treatment in 6 cases, while radiation therapy was given as adjuvant treatment in 10 cases, and as palliative treatment in 3 cases.
The most significant prognostic factors for BCM are stage, tumor size and lymph node status. Hultborn et al. [33] demonstrated that age, tumor size, and lymph node status were the most significant prognostic factors by multivariate analysis among a group of 166 BCM patients. As in women, axillary lymph node status, tumor site, histological grade and hormone receptor status are the most significant prognostic factors in men with breast cancer. However nodal disease is the most important negative prognostic factor. The clinical outcome for men is similar to that for women. The 5-year overall survival rates for all stages range from 36 to 66 [10] .
In our study, as regards the overall 5 years survival, the only significant variables were stage (p = 0.007) and curative surgery (p = 0.011). There were two factors with borderline significance: LN positivity (p = 0.062), with better survival with negative LN cases, and surgery type with better survival with MRM (p = 0.186). The latter is explained by the fact that RM was usually done for more locally advanced disease. Regarding disease free survival, surgery type was the only variable significantly affecting survival (p = 0.002), and stage has a borderline significant effect (p = 0.123).
Conclusion
Breast carcinoma in Egyptian males occurs at older ages than females. The proportion of BCM to BCF is much less than older series 50-70 years ago. There is always a delay in the male patients since the first complaint until they seek medical advice, which results in an advanced disease at presentation. This should be looked after with great concern mainly by directing the attention of males and increasing their awareness on the prevalence and risk factors for this disease. For men who present with non-metastatic disease the recommended surgical therapy is modified radical mastectomy. The majority of our cases of BCM were hormone-receptor positive and tamoxifen plays an important role in most patients.
